Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Johnson & Johnson (NYSE: JNJ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large New Jersey–incorporated healthcare issuer with common stock and multiple series of notes listed on the New York Stock Exchange, Johnson & Johnson reports material events, financial results and capital structure details through forms such as 10-K, 10-Q and 8-K.
Recent Form 8-K filings illustrate how Johnson & Johnson uses current reports to communicate key developments. For example, the company has filed 8-Ks to announce quarterly sales and earnings results for specific fiscal quarters, and to disclose its intent to separate its Orthopaedics business. These filings also list the securities registered under Section 12(b) of the Exchange Act, including the JNJ common stock and various notes with maturities extending from the late 2020s through the 2050s, each with its own NYSE trading symbol.
On this page, users can review Johnson & Johnson’s periodic reports for detailed information on its Innovative Medicine and MedTech operations, risk factors, research and development spending, and manufacturing and investment plans. Annual reports on Form 10-K and quarterly reports on Form 10-Q provide management’s discussion and analysis, segment information and notes to the financial statements, while current reports on Form 8-K highlight specific corporate actions, clinical or regulatory milestones and financing activities as they occur.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand topics such as revenue drivers, major therapeutic areas, MedTech initiatives, capital allocation decisions and announced business changes like the planned Orthopaedics separation. The platform also surfaces relevant items related to Johnson & Johnson’s registered debt securities and any disclosed board or governance actions. For investors, analysts and researchers, this page offers a structured view of Johnson & Johnson’s regulatory record, with real-time updates as new filings are posted to EDGAR.
Johnson & Johnson executive Jennifer Taubert reported an equity award tied to performance. On February 9, 2026, she acquired 27,412 Performance Share Units (PSUs) at a price of $0. These PSUs were originally granted on February 13, 2023 under the company’s Long-Term Incentive Plan.
The 27,412 PSUs represent the target award adjusted based on achievement of performance conditions, which were certified on February 9, 2026. The PSUs convert into shares of Johnson & Johnson common stock upon vesting, so their ultimate value depends on both vesting and the company’s share price at that time.
Johnson & Johnson executive James D. Swanson, EVP and CIO, reported an equity award tied to prior performance. On February 9, 2026, he acquired 9,412 Performance Share Units at a price of $0.00 per unit. These PSUs were originally granted under the company’s Long-Term Incentive Plan on February 13, 2023 and convert into shares of common stock upon vesting.
The 9,412-unit amount reflects the target PSUs from the 2023 grant, adjusted based on achievement of the performance conditions specified in the award agreement, which were certified on February 9, 2026. Following this transaction, Swanson directly holds 9,412 derivative securities in the form of these PSUs.
Johnson & Johnson executive Timothy Schmid reported an equity award tied to performance. On February 9, 2026, he acquired 4,378 Performance Share Units at a price of $0 under the company’s long-term incentive plan. These units were originally granted on February 13, 2023.
The PSUs convert into shares of Johnson & Johnson common stock upon vesting. The 4,378-unit amount reflects the target number from the original grant, adjusted based on achievement of performance conditions that were certified on February 9, 2026. Following this transaction, Schmid directly holds 4,378 derivative securities related to common stock.
Johnson & Johnson executive Kristen Mulholland, EVP and Chief HR Officer, acquired 3,602 Performance Share Units (PSUs) on February 9, 2026. These PSUs were originally granted on February 13, 2023 under the company’s Long-Term Incentive Plan and convert into shares of common stock upon vesting.
The 3,602 PSUs reflect the target award adjusted based on certified achievement of the performance conditions in the award agreement as of February 9, 2026. Following this transaction, Mulholland directly holds 3,602 derivative securities tied to Johnson & Johnson common stock.
Johnson & Johnson reported that EVP and Chief Legal Officer Elizabeth Forminard acquired 13,706 Performance Share Units (PSUs) on February 9, 2026 as a grant under the company’s long-term incentive plan.
The PSUs, originally granted on February 13, 2023, convert into an equal number of Johnson & Johnson common shares upon vesting, with the final number certified based on achievement of performance conditions as of February 9, 2026.
Johnson & Johnson CEO and Chairman Joaquin Duato reported receiving an equity award tied to company performance. On February 9, 2026, he acquired 73,054 Performance Share Units (PSUs) at a price of $0 per unit. These PSUs were originally granted on February 13, 2023 under the long-term incentive plan and convert into an equal number of Johnson & Johnson common shares upon vesting, based on performance conditions that were certified on February 9, 2026.
Johnson & Johnson executive equity award: Vice President and Corporate Controller Robert J. Decker acquired 2,741 Performance Share Units (PSUs) on February 9, 2026 as a grant under the company’s long-term incentive plan. These PSUs were originally granted on February 13, 2023 and convert into shares of common stock upon vesting, with the final number reflecting certified achievement of performance conditions.
Johnson & Johnson executive Kathryn E. Wengel reported an equity award tied to company performance. On February 9, 2026, she acquired 13,706 Performance Share Units at a price of $0 under Johnson & Johnson’s long-term incentive plan.
The PSUs were originally granted on February 13, 2023 and convert into shares of common stock when they vest. The 13,706 units represent the target grant amount adjusted based on achievement of the performance conditions specified in the award agreement, as certified on February 9, 2026. Following this transaction, she directly holds 13,706 derivative securities in the form of PSUs.
Johnson & Johnson executive Vanessa Broadhurst, EVP, Global Corporate Affairs, reported an equity compensation transaction. On February 9, 2026, she acquired 8,594 Performance Share Units (PSUs) at a price of $0 per unit under the company’s long-term incentive plan.
The PSUs were originally granted on February 13, 2023 and convert into shares of Johnson & Johnson common stock upon vesting. The reported 8,594-unit figure reflects the target PSUs adjusted based on achievement of performance conditions, which were certified on February 9, 2026. Following this transaction, she directly holds 8,594 derivative securities linked to common stock.
Johnson & Johnson has filed a shelf registration that allows it to offer debt securities from time to time after the registration becomes effective. The specific terms of each series, including interest structure and maturity, will be set in separate prospectus supplements.
The debt securities will be unsecured obligations issued under an existing indenture and may be sold directly or through agents, dealers, or underwriters. Unless a prospectus supplement states otherwise, net proceeds will be used for general corporate purposes such as working capital, capital expenditures, stock repurchase programs, refinancing of borrowings and acquisitions.